Efficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021 in Healthy and Diabetic Patients

NCT05089942 Phase 4 UNKNOWN

The aim of this study is to investigate the efficacy，safety， and tolerability of the recombinant human insulin patch ZJSRM2021 in healthy subjects, type 1diabetes mellitus and type 2diabetes mellitus patients

Details

Lead sponsor	Zhejiang Provincial People's Hospital
Phase	Phase 4
Status	UNKNOWN
Enrolment	16
Start date	2021-12
Completion	2022-12

Conditions

• type1diabetes
• Type2 Diabetes

Interventions

• Recombinant Human Insulin Patch ZJSRM2021
• Placebo

Primary outcomes

• Efficacy of Recombinant Human Insulin Patch ZJSRM2021 — maximum 1 years
  the glucose and insulin level after receiving Recombinant Human Insulin Patch ZJSRM2021

Countries

China